Shinji Aoyama1, Masahiro Mori2, Akiyuki Uzawa3, Tomohiko Uchida3, Hiroki Masuda3, Ryohei Ohtani3, Satoshi Kuwabara3. 1. Chiba University School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. 2. Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. morim@faculty.chiba-u.jp. 3. Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Abstract
BACKGROUND: The risk of developing progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis (MS) patients is related to serum anti-JCV antibody (JCVAb) index. However, the correlation of JCVAb index with other disease-modifying treatments (DMTs) is not well understood. OBJECTIVE: In this study, we investigated the JCVAb seropositivity rate/JCVAb indexes and its correlation with clinical profiles in Japanese MS patients, and the relationship between JCVAb indexes and DMTs. METHODS: JCVAb indexes were measured in 149 serum samples from 105 patients with MS. JCVAb indexes and seropositivity, and their correlation with age, sex, disease duration, Kurtzke expanded disability status scale and the duration of the DMTs were evaluated in each patient. RESULTS: JCVAb was positive in 73 of 105 MS patients. Within 40 fingolimod-treated patients, 27 were positive for JCVAb and JCVAb indexes were positively correlated with the duration of fingolimod treatment. No significant relation was found between JCVAb indexes and the duration of treatment for the other disease-modifying drugs. CONCLUSION: JCVAb seropositivity was comparatively high in Japanese MS patients. Fingolimod treatment is likely to increase serum JCVAb index, possibly leading to the development of PML. Therefore, it is advised that JCVAb index should be serially monitored during fingolimod treatment to decrease PML risk.
BACKGROUND: The risk of developing progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis (MS) patients is related to serum anti-JCV antibody (JCVAb) index. However, the correlation of JCVAb index with other disease-modifying treatments (DMTs) is not well understood. OBJECTIVE: In this study, we investigated the JCVAb seropositivity rate/JCVAb indexes and its correlation with clinical profiles in Japanese MSpatients, and the relationship between JCVAb indexes and DMTs. METHODS: JCVAb indexes were measured in 149 serum samples from 105 patients with MS. JCVAb indexes and seropositivity, and their correlation with age, sex, disease duration, Kurtzke expanded disability status scale and the duration of the DMTs were evaluated in each patient. RESULTS: JCVAb was positive in 73 of 105 MSpatients. Within 40 fingolimod-treated patients, 27 were positive for JCVAb and JCVAb indexes were positively correlated with the duration of fingolimod treatment. No significant relation was found between JCVAb indexes and the duration of treatment for the other disease-modifying drugs. CONCLUSION: JCVAb seropositivity was comparatively high in Japanese MSpatients. Fingolimod treatment is likely to increase serum JCVAb index, possibly leading to the development of PML. Therefore, it is advised that JCVAb index should be serially monitored during fingolimod treatment to decrease PML risk.
Authors: Annika Antonsson; Adele C Green; Kylie-Ann Mallitt; Peter K O'Rourke; Michael Pawlita; Tim Waterboer; Rachel E Neale Journal: J Gen Virol Date: 2010-03-10 Impact factor: 3.891
Authors: Leonid Gorelik; Michaela Lerner; Sarah Bixler; Mary Crossman; Brian Schlain; Kenneth Simon; Amy Pace; Anne Cheung; Ling Ling Chen; Melissa Berman; Fairuz Zein; Ewa Wilson; Ted Yednock; Alfred Sandrock; Susan E Goelz; Meena Subramanyam Journal: Ann Neurol Date: 2010-09 Impact factor: 10.422
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Moogeh Baharnoori; Jennifer Lyons; Akram Dastagir; Igor Koralnik; James M Stankiewicz Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-08-23
Authors: Su Hyun Kim; Yeseul Kim; Ji Yun Jung; Na Young Park; Hyunmin Jang; Jae Won Hyun; Ho Jin Kim Journal: J Clin Neurol Date: 2019-10 Impact factor: 3.077
Authors: Robert Bonek; Wojciech Guenter; Robert Jałowiński; Anna Karbicka; Anna Litwin; Maciej Maciejowski; Radosław Zajdel; Karolina Zajdel; Veronique Petit; Konrad Rejdak Journal: J Clin Med Date: 2021-05-06 Impact factor: 4.241